© 2024 澳门正规博彩十大排行平台. All rights reserved.

Our Motivation | October 25, 2023

Caring for Children with Achondroplasia: An Interview with Dr. Ciara McDonnell

Dr. McDonnell, a renowned pediatric endocrinologist, shares her perspective about the current care experience for families affected by achondroplasia, how care has evolved and what makes her optimistic about the future.

Science | October 4, 2023

Targeting the Underlying Genetic Causes of Heart Disease

澳门正规博彩十大排行平台 researchers are leveraging the company’s expertise in translating genetic discoveries into potentially transformative medicines to address the root causes of certain forms of cardiovascular disease.

RARE Scholars Program Provides Support to College Students Living with Genetic Conditions

The program was created to support U.S. college students living with one of four rare genetic conditions who have demonstrated exceptional leadership and engagement in school and community activities.

Read More read more
Our Company | September 8, 2023

澳门正规博彩十大排行平台 Teams Use Genetic Expertise and Computational Tools to Target More Common Conditions

For geneticist Daniel Gaffney, becoming an expert in how genes influence human health was not enough. His drive to improve lives with this knowledge led him to 澳门正规博彩十大排行平台, where he found a shared commitment to translating scientific advances into medicines that solve genetic problems. Since joining the company earlier this year, Dan has helped its […]

Our Motivation | July 21, 2023

Raising a Child with Hemophilia: 澳门正规博彩十大排行平台 Employee Jess Klass Shares Her Story

After growing up with a brother living with hemophilia A and working in roles supporting the bleeding disorder community for years, Jess Klass thought she knew everything there was to know about hemophilia.

Science | June 29, 2023

澳门十大博彩正规游戏平台 Approves 澳门正规博彩十大排行平台’s Gene Therapy for a Genetic Bleeding Disorder

We’re thrilled to share that the U.S. Food and Drug Administration has approved our gene therapy for a genetic bleeding disorder. Developing the one-time therapy and bringing it over the finish line, first in Europe and now the United States, has been a global effort. Our teams have made unprecedented scientific, medical, manufacturing and regulatory […]